Skip to main content

Advertisement

SpringerLink
Log in

Immuno-Oncology in Cancer Care is a Fantastic Opportunity for Interventional Oncology: IO4IO (Interventional Oncology for Immuno-Oncology) Initiative

  • Editorial
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I. Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res. 2016;22(8):1845–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Puzanov I, Milhem MM, Minor D, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34(22):2619–26.

    Article  CAS  PubMed  Google Scholar 

  4. Yamazaki T, Pitt JM, Vetizou M, et al. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. Cell Death Differ. 2016;23(6):1004–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Aznar MA, Tinari N, Rullan AJ, Sanchez-Paulete AR, Rodriguez-Ruiz ME, Melero I. Intratumoral delivery of immunotherapy—act locally, think globally. J Immunol. 2017;198(1):31–9.

    Article  CAS  PubMed  Google Scholar 

  6. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–74.

    Article  CAS  PubMed  Google Scholar 

  7. Chew V, Lee YH, Pan L, et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut. 2018. https://doi.org/10.1136/gutjnl-2017-315485

    PubMed  Google Scholar 

  8. den Brok MH, Sutmuller RP, van der Voort R, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 2004;64(11):4024–9.

    Article  Google Scholar 

  9. Lizotte PH, Ivanova EV, Awad MM, et al. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. JCI Insight. 2016;1(14):e89014.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–92.

    Article  CAS  PubMed  Google Scholar 

  11. Ledford H. Immunotherapy’s cancer remit widens. Nature. 2013;497(7451):544.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Interventional Radiology, Gustave Roussy Cancer Center, 114 Rue Edouard Vaillant, Villejuif, France

    Thierry de Baère, Lambros Tselikas & Frederic Deschamps

  2. Universite Paris-Sud XI, UFR Médecine, Le Kremlin-Bicêtre, France

    Thierry de Baère, Lambros Tselikas, Frederic Deschamps, Jean Charles Soria & Aurélien Marabelle

  3. Department of Therapeutic Innovations and Early Clinical Studies, Gustave Roussy Cancer Center, 114 Rue Edouard Vaillant, 94 805, Villejuif, France

    Jean Charles Soria & Aurélien Marabelle

Authors
  1. Thierry de Baère
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lambros Tselikas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frederic Deschamps
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean Charles Soria
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aurélien Marabelle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thierry de Baère.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de Baère, T., Tselikas, L., Deschamps, F. et al. Immuno-Oncology in Cancer Care is a Fantastic Opportunity for Interventional Oncology: IO4IO (Interventional Oncology for Immuno-Oncology) Initiative. Cardiovasc Intervent Radiol 41, 825–827 (2018). https://doi.org/10.1007/s00270-018-1935-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-018-1935-y

Keywords

Search

Navigation